Synthetic Molecule(s)
Non-Small Cell Lung Cancer (NSCLC)
Key Facts
About ABVC BioPharma
ABVC BioPharma's mission is to develop and commercialize novel therapeutics derived from botanical compounds and synthetic molecules. Its key achievements include advancing multiple assets into clinical trials for conditions like Major Depressive Disorder (MDD), ADHD, and various solid tumors. The company's strategy leverages both internal R&D and external academic collaborations to navigate the capital-intensive drug development pathway, aiming to create value through clinical milestones and potential partnerships.
View full company profileAbout ABVC BioPharma
ABVC BioPharma's mission is to develop and commercialize novel therapeutics derived from botanical compounds and synthetic molecules. Its key achievements include advancing multiple assets into clinical trials for conditions like Major Depressive Disorder (MDD), ADHD, and various solid tumors. The company's strategy leverages both internal R&D and external academic collaborations to navigate the capital-intensive drug development pathway, aiming to create value through clinical milestones and potential partnerships.
View full company profileTherapeutic Areas
Other Non-Small Cell Lung Cancer (NSCLC) Drugs
| Drug | Company | Phase |
|---|---|---|
| LW-02 Immunopheresis | Immunicom | Phase 2 |
| Idylla EGFR Mutation Assay | Biocartis | Approved |
| ABD-3001 | Advanced Biodesign | Phase 1 |
| Macrocyclic OMNI-EGFR Inhibitor | BlossomHill Therapeutics | Phase 1 |
| TUMORIN Clinical Trial | Nilogen Oncosystems | N/A (Diagnostic Validation) |
| Membrex™ | Metaclipse Therapeutics | Pre-clinical |
| Lazertinib (Leclaza) | Genosco | Approved |
| IPH5201 (anti-CD39 mAb) | Orega Biotech | Phase 2 |
| Platin-DRP® | Chosa Oncology | Validation |
| Undisclosed RNA Immunotherapy | Epitopea | Pre-clinical |
| Aspyre Clinical Test for Lung | Biofidelity | Commercial |
| EGFR Mutation Detection Assay | Stilla Technologies | Assay Development/Validation |